Abstract
100-hue test, 412
3092 T → C polymorphism, 1078
acetazolamide, 344
acetylsalicylic acid, 776
acupuncture, 41
adenosine, 369, 1082
adolescent, 333, 433, 482
allodynia, 735
altitude cephalea, 1110
altitude headache, 1110
altitude sickness, 1110
amitriptyline, 1048
analgesic-overuse headache, 378
analgesic rebound headache, 132
apnoea, 488
arteriovenous anastomoses, 1082
atypical cluster headache, 1068
auditory psychophysics, 60
aura, 444
bath-related headache, 191
BIBN4096BS, 139
biological rhythms, 811
blood patch, 523
brainstem, 109
butalbital, 726
caffeine, 776
calcitonin gene-related peptide, 700
calcitonin gene-related peptide (CGRP), 179
capsaicin, 1082
carotid haemodynamics, 1082
CBF, 23, 344
cell adhesion, 536
central sensitization, 359, 735
cerebral and systemic haemodynamics, 139
cerebral blood flow, 323, 369
cervical artery dissection, 575
cervical spine, 1133
cervicogenic headache, 101, 700
c-fos expression, 225
CGRP-antagonism, 139
CGRP receptor, 424
CGRP release, 225
chaos, 561
children, 280, 1042
chronic daily headache, 482, 795
chronic migraine, 378, 482, 795
chronic post-traumatic headache, 132
chronic tension type headache, 704, 795
chronic-migraine, 391
clamp, 593
classification, 460, 801
classification criteria, 1042
clinical difference, 244
clinical features, 689
clinical study, 1031
clock gene, 1078
closed cranial window model, 23
cluster headache, 36, 82, 244, 290, 403, 488, 605, 1068, 1078
colour, 412
combination analgesic, 776
comorbidity, 519
computed tomography, 30
computer-aided pressure algesimetry, 205
contact point, 439
cortical hyperexcitability, 811
cortical pial arteries, 424
cranial neuralgias, 305
critical flicker frequency, 339
cutaneous allodynia, 75
depression, 598
diagnosis, 30, 117, 801
disability, 184, 452, 598
disability and treatment, 1122
dose–response, 715
dot kinetogram, 788
drug-induced headache, 391
drug-overuse, 391
DTC, 776
dural and pial arteries, 23, 249
duration estimation, 60
economic evaluation, 709
efficacy, 1031
Eletriptan, 715, 726, 735
Emergency department, 199
encapsulation, 715
endothelium and vascular smooth muscle cells, 424
epidemiology, 267, 1146
epilepsy, 82, 528
ergotamine, 214
ergotamine-overuse headache, 378
ethics, 124
evidence-based medicine, 767
exercise, 101, 1061
experimental model, 1061
exposure, 685
extracranial vasodilation, 16
facial pain, 689
familial, 457
familial hemiplegic migraine, 817
feverfew, 1031
flicker frequency threshold, 339
flunarizine, 1048
forehead trauma, 296
France, 184
gene expression, 1117
general practitioners, 184, 767
genetic, 457
genetic association study, 1078
genetics and clinical symptoms, 1068
glibenclamide, 249
GR79236, 1082
greater occipital nerve, 704
guidelines, 767
habituation, 280
headache, 30, 48, 109, 117, 179, 191, 199, 219, 444, 457, 493, 523, 581, 709, 726, 776, 1054
headache centre, 1159
headache clinic, 1122
headache disorders, 460
headache epidemiology, 581
health care use, 267
health economics, 709
healthcare use, 493
hereditary vascular retinopathy, 1168
human, 261
hyperexcitability, 788
hypotension, 23
hypoxia, 1117
IDAP, 36
idiopathic stabbing headache, 296, 581
IHC diagnostic criteria, 132
IHS criteria, 333
incidence, 433
inflammation, 536
insulin sensitivity, 593
integrative medicine, 493
international classification of headache disorders, 689
Italy, 767
jabs, 296
jabs and jolts syndrome, 581
KATP channels, 249
lacrimation, 457
lactate, 507
laser evoked potentials, 359
leptin, 1048
levcromakalim, 249
L-NMMA, 344
locus, 1168
low back pain, 598
low cerebrospinal fluid pressure, 523
lumbar puncture, 523
magnesium sulphate, 199
magnetic resonance imaging, 30
manipulative therapy, 101
maturation, 280
medication overuse, 1159
medication-overuse headache, 378, 460
medication overuse headache, 12, 493, 519
melatonin, 403
menstrual, 41
meta-analysis, 715
metabolism, 507
metoclopramide, 199
MIDAS, 452
middle cerebral artery, 424
migraine, 1, 16, 41, 48, 56, 60, 75, 82, 87, 117, 124, 139, 165, 179, 184, 199, 219, 225, 261, 267, 280, 333, 339, 353, 359, 369, 403, 412, 433, 439, 452, 507, 519, 528, 536, 542, 561, 567, 575, 581, 593, 598, 605, 700, 726, 735, 767, 776, 788, 811, 817, 1042, 1048, 1082, 1117, 1122, 1133 1168
migraine aura, 323
migraine mechanisms, 339
migraine pain relief, 715
migraine treatment, 1103
migraine with aura, 801
migraine with persistent aura, 323
migraine with prolonged aura, 323
motion perception, 788
motion sickness, 16, 219
MRS, 507
multidisciplinary, 1159
Na+/K+ATPase, 1117
nasal administration, 1103
nausea, 16, 219
nerve block, 704
neuromuscular transmission, 817
neurovascular, 48
Neurovascular coupling, 567
new daily persistent headache, 795
nitric oxide, 225
nitroglycerin, 179, 612
nociceptin, 109, 261
non-linear, 561
nonpharmacological, 41
OGIS-180, 593
OP-4 receptor, 261
oriental female, 191
outcomes, 101
P/Q Ca2+ channels, 817
PaCO2, 23
pain, 1054
pain quantification, 205
paracetamol, 776
paroxysmal hemicrania, 244
parthenolide, 612
pathophysiology, 403, 444, 704
perfusion MRI, 56
pericranial muscles, 1061
periodicity, 1078
peroxynitrite, 353
persistent aura, 56
persistent idiopathic facial pain, 689
pinacidil, 249
pineal gland, 403
placebo, 41, 124
placebo addiction, 391
plasma CGRP levels, 1082
plasticity, 109
platelet aggregation, 536
platelet membrane, 353
platelets, 536
polysomnography, 488
porcine, 1082
positron emission tomography, 1103
post-traumatic pain development, 205
predictors, 101
pregnancy, 685
prescription data, 214
prevalence, 333, 433
preventive medicines, 1
probable migraine, 184, 1146
prodrome, 444
prognosis, 528
psychiatric comorbidity, 165, 1146
psychiatric disorder, 519
psychological factors, 1054
quality of life, 87, 1122, 1146
questionnaire, 811
range of motion, 1133
rat, 225
rat brain, 612
rating scale, 801
Raynaud's phenomenon, 1168
recurrence/relapse, 267
red ear syndrome, 605
referred pain, 75
refractory headache, 439
relapse, 12
reliability, 1133
rheumatic fever, 542
risk, 575
risk factors, 333
rizatriptan, 685
safety, 1031
S-cone deficit, 412
seasonal variation, 811
sensitivity, 1042
serotonergic neurotransmission, 36
shortlasting headaches, 305
side-effects, 1
single-fibre electromyography, 817
somatostatin, 48
specific antimigraine drugs, 214
specificity, 1042
SPECT, 56, 344
steroid therapy, 290
sumatriptan, 179, 715
SUNCT, 305, 457
supraorbital nerve, 296
supraorbital neuralgia, 296
surgical treatment, 439
survey, 493
Sydenham's chorea, 542
symptomatic treatment, 290, 359
symptoms, 117
systematic review, 124
TACs, 457
Tanacetum parthenium, 612, 1031
TCD, 344, 567
temporomandibular disorders, 1054
tenderness, 1061
tension-type headache, 598, 1061
therapeutic management, 1146
thunderclap headache, 191
time perception, 60
TMD, 1054
transcranial Doppler, 369
transformed migraine, 165, 378, 482
transitional prophylaxis, 290
treatment, 403
treatment outcome, 1159
trigeminal, 109
trigeminal autonomic cephalgia, 605
trigeminal nerve, 704
trigeminal nerve stimulation, 16
trigeminal neuralgia, 305, 689
trigeminal nucleus caudalis, 225
trigeminovascular activation, 700
Trigeminovascular system, 261
trigger factors, 444
trigger point, 439
triptan, 12, 124, 214, 267, 726, 735
usage patterns, 214
V5, 788
vagus nerve stimulation, 82
validity, 1133
variability, 117
vascular comorbidity, 593
vision, 412
visual evoked potential, 280, 567
visual stimultion, 507
visual symptoms, 801
visual system, 339
visually evoked cerebral blood flow responses, 567
water diffusion, 323
weight, 1
weight gain, 1048
whiplash injury, 205
willingness to pay, 87
zolmitriptan, 1103